Greenwich LifeSciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| Common Stock · Additional · Total | |||||
|---|---|---|---|---|---|
| Shares | Par Amount | Paid-in Capital | Accumulated Deficit | Stockholders’ Equity | |
| Balances, December 31, 2022 | 12,848,165 | $12,848 | $54,674,042 | $(41,472,766) | $13,214,124 |
| Stock-based compensation | — | — | 2,378,088 | — | 2,378,088 |
| Net loss | (8,891,803) | (8,891,803) | |||
| Balances, December 31, 2023 | 12,848,165 | $12,848 | $57,052,130 | $(50,364,569) | $6,700,409 |
| Stock-based compensation | — | — | 7,253,327 | — | 7,253,327 |
| Sale of common stock via ATM program, net of costs | 129,739 | 130 | 1,868,981 | — | 1,869,111 |
| Sale of common stock via Private Placement, net of costs | 174,825 | 175 | 2,499,823 | — | 2,499,998 |
| Net loss | (15,788,809) | (15,788,809) | |||
| Balances, December 31, 2024 | 13,152,729 | $13,153 | $68,674,261 | $(66,153,378) | $2,534,036 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.